Current diagnostic approaches predominantly depend on late-onset clinical features (e.g., proteinuria, hypertension) and suboptimal biomarkers such as soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1/PlGF) ratio, which significantly constrains timely clinical intervention. The gene discussed is PGF; the disease is Hypertension.